Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million worth of Binance Coin (BNB) after it recently reached an all-time high of $808. The company is raising approximately $520 million to facilitate these purchases, significantly increasing its commitment from an earlier announcement of $200 million. The funds will be sourced through a $500 million equity line of credit and a $20 million stock-purchase agreement with another firm. Windtree's strategy aligns with a growing trend of publicly traded companies acquiring cryptocurrencies to enhance their balance sheets, following the lead of firms like Strategy. Despite a recent decline in its stock price, Windtree's shares have surged by 162% over the past month. BNB is currently the fifth-largest cryptocurrency by market capitalization, valued at $769 according to CoinGecko. The shift towards cryptocurrency acquisitions by companies like Windtree demonstrates a significant shift in financial strategy to boost stock value and engage with digital assets.

Source đź”—